(RS)-1-Benzyloxycarbonyl-4-(1-hydroxyethyl)piperidine | 160809-35-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (RS)-1-Benzyloxycarbonyl-4-(1-hydroxyethyl)piperidine
• 英文别名: 1-benzyloxycarbonylpiperidin-4-ylethanol；(+/-)-phenylmethyl 4-(1-hydroxyethyl)-1-piperidinecarboxylate；4-(1-hydroxyethyl)piperidine-1-carboxylic acid benzyl ester；(R,S)-N-benzyloxycarbonyl-4-[1'-(hydroxy)ethyl]piperidine；Benzyl 4-(1-hydroxyethyl)piperidine-1-carboxylate
• CAS: 160809-35-8
• 化学式: C₁₅H₂₁NO₃
• 分子量: 263.337
• InChiKey: FBYCYHVEXKSMCW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (RS)-1-Benzyloxycarbonyl-4-(1-hydroxyethyl)piperidine 、 2-(2-isopropyl-5-methyl-2H-[1,2,4]triazol-3-yl)-4,5-dihydro-6-oxa-1,3a-diazabenzo[e]azulen-8-ol 在 偶氮二甲酸二异丙酯 、 三苯基膦 作用下， 以 1,4-二氧六环 为溶剂， 反应 18.0h， 以20%的产率得到4-{1-[2-(2-isopropyl-5-methyl-2H-[1,2,4]triazol-3-yl)-4,5-dihydro-6-oxa-1,3a-diazabenzo[e]azulen-8-yloxy]ethyl}piperidine-1-carboxylic acid benzyl ester
  参考文献：
  名称：

  BENZOXAZEPIN COMPOUNDS SELECTIVE FOR PI3K P110 DELTA AND METHODS OF USE

  摘要：

  本句翻译为中文是：苯并恶唑啉I型化合物，包括立体异构体、几何异构体、互变异构体、代谢物以及药学上可接受的盐，对于抑制PI3K的δ异构体以及治疗由脂质激酶介导的疾病如炎症、免疫疾病和癌症是有用的。公开了使用I型化合物公式进行体外、原位和体内诊断、预防或治疗哺乳动物细胞中此类疾病或相关病理状况的方法。

  公开号：

  US20120245144A1
• 作为产物：
  描述：

  甲基溴化镁 、 4-甲酰基-N-CBZ 哌啶 在 氯化铵 、 乙醚 、 Brine 、 Sodium sulfate-III 、 crude product 、 silica gel 作用下， 以 乙醚 为溶剂， 反应 2.0h， 以to give 0.64 g (62%) of (±)-phenylmethyl 4-(1-hydroxyethyl)-1-piperidinecarboxylate as a colorless oil的产率得到(RS)-1-Benzyloxycarbonyl-4-(1-hydroxyethyl)piperidine
  参考文献：
  名称：

  BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS

  摘要：

  本发明涉及一种新型化合物，其在代谢性疾病的治疗中具有用途，特别是在II型糖尿病及相关疾病的治疗中，并且还涉及制备和使用这种化合物的方法。

  公开号：

  US20100029650A1

文献信息

• Heterocyclic compouds
  申请人：Zeneca Limited

  公开号：US05753659A1

  公开（公告）日：1998-05-19

  A compound of the general formula (M.sup.1).sub.n --Q--(M.sup.2).sub.1-n --L--A I wherein: n is 0 or 1; M.sup.1 is an amino group; Q is an aromatic heterocyclic group containing a basic nitrogen atom; M.sup.2 is an imino group; L is a template group; and A is an acidic group, or an ester or amide derivative thereof, or a sulphonamide group; and pharmaceutically acceptable salts and pro-drugs thereof, for use in the treatment of a disease in which platelet aggregation mediated by the binding of adhesion molecules to GPIIb-IIIa is involved. Novel compounds are also disclosed.

  通式（M.sup.1).sub.n --Q--(M.sup.2).sub.1-n --L--A I的化合物，其中：n为0或1；M.sup.1为氨基；Q为含有碱性氮原子的芳香杂环基团；M.sup.2为亚胺基；L为模板基团；A为酸性基团，或其酯或酰胺衍生物，或磺酰胺基团；以及其药学上可接受的盐和前药，用于治疗通过粘附分子结合到GPIIb-IIIa介导的血小板聚集参与的疾病。还披露了新的化合物。
• [EN] 4-SUBSTITUTED PIPERIDINE DERIVATIVES<br/>[FR] DERIVES DE PIPERIDINE SUBSTITUES EN POSITION 4
  申请人：BIOAXONE THERAPEUTIQUE INC

  公开号：WO2005080394A1

  公开（公告）日：2005-09-01

  Substituted piperidine compounds represented by the structure I are provided, wherein each of Rla, R1b, R1c, R1d, Rle, R1f, R1g, R1h, R2, R2A, R3, R4, A, X, a, x, and n is as defined in the specification. Substituted piperidine compounds of structure I may permeate or penetrate across a nerve cell membrane into the interior of a nerve cell, may inhibit intracellular Rho kinase enzyme found in nerve cells in mammals, and may find utility in repair of damaged nerves in the central and peripheral nervous system of such mammals. These compounds may induce the regeneration or growth of neurites in mammalian nerve cells and may thereby induce regeneration of damaged or diseased nerve tissue. These compounds also find additional utility as antagonists of the enzyme Rho kinase in treatment of disease states in which Rho kinase is implicated. Pharmaceutical compositions containing these substituted piperidine compounds may be useful to promote neurite growth and in the treatment of diseases in which Rho kinase inhibition is indicated.

  提供了由结构I表示的取代哌啶化合物，其中Rla、R1b、R1c、R1d、Rle、R1f、R1g、R1h、R2、R2A、R3、R4、A、X、a、x和n中的每一个如规范中定义。结构I的取代哌啶化合物可能渗透或穿过神经细胞膜进入神经细胞内部，可能抑制哺乳动物神经细胞中的细胞内Rho激酶酶，并可能在这些哺乳动物的中枢和外周神经系统中修复受损神经时发挥作用。这些化合物可能诱导哺乳动物神经细胞中神经突起的再生或生长，从而诱导受损或患病神经组织的再生。这些化合物还可作为Rho激酶酶拮抗剂在治疗涉及Rho激酶的疾病状态中发挥额外作用。含有这些取代哌啶化合物的药物组合物可能有助于促进神经突起的生长，并在需要Rho激酶抑制的疾病治疗中发挥作用。
• 4-Substituted piperidine derivatives
  申请人：McKerracher Lisa

  公开号：US20050272751A1

  公开（公告）日：2005-12-08

  Substituted piperidine compounds represented by the structure I are provided, wherein each of R 1a , R 1b , R 1c , R 1d , R 1e , R 1f , R 1g , R 1h , R 2 , R 2A , R 3 , R 4 , A, X, a, x and n is as defined in the specification. Substituted piperidine compounds of structure I may permeate or penetrate across a nerve cell membrane into the interior of a nerve cell, may inhibit intracellular Rho kinase enzyme found in nerve cells in mammals, and may find utility in repair of damaged nerves in the central and peripheral nervous system of such mammals. These compounds may induce the regeneration or growth of neurites in mammalian nerve cells and may thereby induce regeneration of damaged or diseased nerve tissue. These compounds also find additional utility as antagonists of the enzyme Rho kinase in treatment of disease states in which Rho kinase is implicated. Pharmaceutical compositions containing these substituted piperidine compounds may be useful to promote neurite growth and in the treatment of diseases in which Rho kinase inhibition is indicated.

  提供了由结构式I表示的取代哌啶化合物，其中R1a、R1b、R1c、R1d、R1e、R1f、R1g、R1h、R2、R2A、R3、R4、A、X、a、x和n的定义如规范中所述。结构式I的取代哌啶化合物可以渗透或穿过神经细胞膜进入神经细胞内部，可以抑制哺乳动物神经细胞中发现的细胞内Rho激酶酶，并可用于修复哺乳动物中心和周围神经系统中的受损神经。这些化合物可以诱导哺乳动物神经细胞的轴突再生或生长，从而诱导受损或患病的神经组织再生。这些化合物还可作为Rho激酶酶拮抗剂，在治疗涉及Rho激酶酶的疾病状态中发现其他用途。含有这些取代哌啶化合物的制药组合物可用于促进神经轴突生长，并用于治疗需要Rho激酶抑制的疾病。
• Heterocyclic compounds
  申请人：Zeneca Limited

  公开号：US05563141A1

  公开（公告）日：1996-10-08

  A compound of the general formula (M.sup.1).sub.n --Q--(M.sup.2).sub.1-n --L--A I wherein: n is 0 or 1; M.sup.1 is an amino group; Q is an aromatic heterocyclic group containing a basic nitrogen atom; M.sup.2 is an imino group; L is a template group; and A is an acidic group, or an ester or amide derivative thereof, or a sulphonamide group; and pharmaceutically acceptable salts and pro-drugs thereof, for use in the treatment of a disease in which platelet aggregation mediated by the binding of adhesion molecules to GPIIb-IIIa is involved. Novel compounds are also disclosed.

  一种通式为(M.sup.1).sub.n --Q--(M.sup.2).sub.1-n --L--A I的化合物，其中：n为0或1；M.sup.1为氨基基团；Q为含有碱性氮原子的芳香杂环基团；M.sup.2为亚胺基团；L为模板基团；A为酸性基团，或其酯或酰胺衍生物，或磺酰胺基团；以及其医药上可接受的盐和前药，用于治疗与 GPIIb-IIIa 结合的粘附分子介导的血小板聚集相关的疾病。还公开了新型化合物。
• Bicyclic compounds and use as antidiabetics
  申请人：GlaxoSmithKline LLC

  公开号：US08101634B2

  公开（公告）日：2012-01-24

  The present invention relates to novel compounds that are useful in the treatment of metabolic disorders, particularly type II diabetes mellitus and related disorders, and also to the methods for the making and use of such compounds.

  本发明涉及一种新型化合物，可用于治疗代谢性疾病，特别是II型糖尿病及相关疾病，并且还涉及制备和使用这种化合物的方法。